Mogrify: Funding, Investors & Team (Oct 2026)
Mogrify has created a set of unique technology platforms that use a systematic approach involving big data to reprogram and maintain the identity of cells. These platforms, known as MOGRIFY and epiMOGRIFY, were developed over a 12-year period through a collaboration between multiple nations. They utilize next-generation sequencing and data on gene regulation and epigenetics to predict the transcription factors and growth factors needed to convert any human cell type into another. The platforms can improve existing methods of stem cell programming or directly transform one mature cell type into another, bypassing traditional development pathways. Mogrify is utilizing these platforms to generate functional cell types that can treat various degenerative diseases in areas such as ophthalmology, otology, and metabolism. With an estimated market value of $150 billion USD in regenerative medicine by 2028, Mogrify plans to commercialize its technology through the development of in vivo reprogramming therapies, collaborative partnerships, and exploration of other therapeutic and non-therapeutic applications.
Mogrify has raised $10.0M across 1 funding round on record, the most recent a Series A of $10.0M announced in Oct 2023.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Mogrify Company Profile and Key Stats
Latest funding round on record: Oct 2023.
Mogrify Funding Rounds
Mogrify Founders and Leadership Team
Contact details for the Mogrify team: 1 of 1 has an email address on file.
Start 14-day free trial →Mogrify Funding Compared to Other Biotechnology Startups
Mogrify's latest round of $10.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Mogrify in Biotechnology and Cambridge
Companies Similar to Mogrify
R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug…
The perfect package for any general surgical trainee or resident. Progress from beginner to advanced surgical…
Argonaute RNA company research projects build on existing intellectual property.
An innovative C elegans company that serves the biotech, nutrition, and other industries and fields of study…
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
Mogrify Funding FAQs
What does Mogrify do?
Mogrify has created a set of unique technology platforms that use a systematic approach involving big data to reprogram and maintain the identity of cells. These platforms, known as MOGRIFY and epiMOGRIFY, were developed over a 12-year period through a collaboration between multiple nations. They utilize next-generation sequencing and data on gene regulation and epigenetics to predict the transcription factors and growth factors needed to convert any human cell type into another. The platforms can improve existing methods of stem cell programming or directly transform one mature cell type into another, bypassing traditional development pathways. Mogrify is utilizing these platforms to generate functional cell types that can treat various degenerative diseases in areas such as ophthalmology, otology, and metabolism. With an estimated market value of $150 billion USD in regenerative medicine by 2028, Mogrify plans to commercialize its technology through the development of in vivo reprogramming therapies, collaborative partnerships, and exploration of other therapeutic and non-therapeutic applications.
How much funding has Mogrify raised?
Mogrify has raised $10.0M across 1 round on record. The most recent is a Series A of $10.0M announced in Oct 2023.
When did Mogrify last raise funding?
Mogrify's most recent funding round on record is a Series A of $10.0M, announced in Oct 2023.
Who founded Mogrify?
FundedIQ lists Owen Rackham (Founder) at Mogrify.
Where is Mogrify headquartered?
Mogrify is based in Cambridge, Cambridgeshire, United Kingdom.
How many employees does Mogrify have?
Mogrify is in the 51-100 employee band.
How does Mogrify's funding compare to other Biotechnology startups?
Mogrify's latest round of $10.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Mogrify Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Mogrify is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.